The World Health Organization has placed the first molecular test for the Bundibugyo virus on its Emergency Use Listing. The test detects a filovirus that has caused deadly outbreaks in Uganda and the Democratic Republic of the Congo but until now had no dedicated diagnostic tool approved for emergency use.
A test designed for a virus that hides in plain sight
Bundibugyo virus belongs to the same family as Ebola. It was first identified in 2007 during an outbreak in Uganda's Bundibugyo District. Since then, it has reappeared in the Democratic Republic of the Congo in 2012 and again in Uganda in 2014. Symptoms include fever, vomiting, diarrhea, and in severe cases, internal bleeding. Because these signs look like other viral hemorrhagic fevers, health workers have struggled to tell it apart from Ebola or Marburg without laboratory confirmation.
The new test, called the Altona Diagnostics RealStar Filovirus Screen RT PCR Kit 2.0, runs on standard PCR equipment. It detects Bundibugyo virus genetic material in blood samples. The WHO listing means the test meets international standards for quality, safety, and performance. Countries can now procure and use it during outbreaks without going through separate lengthy approval processes.
Why local health workers pushed for faster detection
In rural Uganda, where the virus first emerged, hospitals often lack advanced labs. Samples must travel to the Uganda Virus Research Institute in Entebbe or to reference labs abroad. That delay can take days. During that time, patients may die undiagnosed, and the virus can spread to caregivers and family members.
Local health officials have long called for a test that can be deployed quickly in field settings. The WHO listing does not guarantee the test will be available in every clinic tomorrow, but it clears a major regulatory hurdle. Manufacturers can now supply the test to countries at risk, and international health agencies can stockpile it for rapid response.
A quiet step with loud implications for outbreak control
The Emergency Use Listing process was created during the 2014 2016 Ebola outbreak in West Africa. It allows the WHO to fast track medical products during public health emergencies. For Bundibugyo virus, this is the first time any diagnostic has received that status.
Without a licensed vaccine or specific treatment for Bundibugyo virus, early detection is the main defense. The test gives health workers a tool to identify cases sooner, isolate patients faster, and trace contacts before the virus gains momentum. For communities that have lived through outbreaks, that difference can mean fewer funerals and less fear.
